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Abstract
Patients with COVID-19 may have co-infections with other microorganisms. Here we report a case of a patient with an Escheria coli bacteremia secondary to a urinary tract infection,
who experienced fevers while on active antimicrobial therapy.

The patient was eventually tested for COVID-19 and found
to be positive. This case emphasizes the need to suspect
COVID-19 even in patients with documented bacterial infection.

Introduction

tion throughout his hospitalization.

Current CDC guidance encourages health care
providers to consider testing for SARS-CoV-2 infection
in patients with signs and symptoms consistent with
COVID infection.[1] Reports of both viral and bacterial co-infection are now emerging.[2-6] We describe a
patient with Escherichia coli bacteremia secondary to a
urinary tract infection, who developed persistent high
fevers despite receiving appropriate antimicrobial therapy based on susceptibility results. Due to clinical deterioration, the patient was tested for novel coronavirus
infection and found to have a positive nasopharyngeal
PCR. Our case report serves as a caution against ruling
out SARS-CoV-2 when another infectious process may
not fully explain a patient’s symptoms.

On hospital day 2, the patient had a urinary catheter
placed due to continued urinary retention. He also reported diarrhea and was tested for C. difficile infection,
which was negative. Repeat blood cultures were obtained and demonstrated no growth, confirming clearance of the patient’s bacteremia.

Case Presentation
A 64-year-old white male presented to the emergency
department with a chief complaint of burning with urination starting 4 days prior to admission. His past
medical history was significant for type 2 diabetes
mellitus, hypertension and pancreatitis. The patient
also endorsed urinary retention, gait instability, nausea,
vomiting and chills. Blood and urine cultures were collected, both of which grew pan-susceptible E. coli. The
patient received active antibiotics for his E. coli infec-
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On hospital day 4, a CT of the abdomen/pelvis was
obtained, which noted an evolving prostate abscess
(Figure 1). Of note, the patient also began reporting a
dry cough and developed high fevers with a maximum
temperature of 103.4 °F. That evening, he required BiPAP in order to maintain SaO2>90%. He was eventually intubated due to respiratory failure. At this point, a
nasopharyngeal COVID-19 PCR test was obtained due
to rapid clinical deterioration despite adequate management of the patient’s bacterial infection. The patient
was also placed into COVID-19 appropriate isolation.
The patient went on to develop multi-organ failure,
including acute respiratory distress syndrome (Figure
2), and required continuous renal replacement therapy and multiple vasopressors to maintain MAP>65
mmHg. On hospital day 9, the COVID-19 PCR test resulted positive, confirming COVID-19 coinfection. At
this time, the patient was non-responsive off sedation
and was compassionately extubated shortly thereafter.
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Figure 1. CT abdomen/pelvis obtained on hospital day 2. Findings significant for 1) enlarged prostate, seminal vesicles and thick-walled urinary
bladder (not visualized here), and 2) new focal 2×1.3 cm region of decreased attenuation at the right lateral periphery of the prostate. It is
unclear if this represents phlegmon/early abscess in the setting of prostatitis.

Discussion
SARS-CoV-2 can present with a constellation of nonspecific symptoms. In our patient, nausea and diarrhea
were possibly the first COVID-19 related symptoms to
present. This was followed by a non-productive cough,
fevers, and eventual respiratory decompensation.[7, 8]
Initially, the patient’s fevers while on antibiotics were
thought to be attributable to his undrained prostate abscess. However, given that this patient was initially
afebrile and then developed high fevers while receiving antibiotics, this raised suspicion for a second infectious process. The median incubation period of SARSCoV-2 appears to be about 5 days.[9-11] Lauer et al. reported that in their cohort, <2.5% of patients displayed
any symptoms within 2.2 days.[9] Based on this information, it seems most likely that our patient acquired
COVID-19 prior to presenting to the hospital.
Guidelines from the Surviving Sepsis Campaign suggest that based on current evidence, the presence of
another respiratory pathogen does not necessarily rule
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out the possibility of COVID-19.[12] In this case, there
was delay in clinical suspicion and COVID-19 testing.
During the first four days of hospitalization, the patient was not in isolation resulting in numerous healthcare worker exposures. This highlights the importance
of the aforementioned recommendation. Universal patient screening upon admission may have identified
this patient as a COVID-19 case earlier.
Clinical outcomes in patients with COVID-19 and
bacterial coinfections have not been well-described.
Fan and colleagues describe a case of a patient with
COVID-19 and Mycoplasma pneumoniae infection.[3]
These authors suggest that failing to treat other causes
of infection in COVID-19 patients is likely to increase
morbidity and mortality.
Worse outcomes were observed in patients with bacterial coinfection and H1N1 influenza. These patients
were more likely to require mechanical ventilation and
longer ICU stays than patients without coinfection.[13]
Additionally, patients with bacterial coinfection had an
2
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Figure 2. CT chest obtained on hospital day 5. Findings include extensive bilateral dense consolidation involving the upper and lower lobes.
There is a small left pleural effusion. Overall appearance is consistent with widespread pneumonia and acute respiratory distress syndrome
(ARDS).

inpatient mortality rate of 31%, versus 21% in patients
with influenza alone (P=0.002).[13] It is possible that
similar outcomes may be observed in the SARS-CoV-2
pandemic, but further data is needed before any conclusions may be drawn.

In conclusion, this case highlights the importance of
considering COVID-19 infection even in the setting of
a confirmed alternate infectious diagnosis. Clinicians
should consider isolation and testing for coinfection if
clinically appropriate.
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